Trial Outcomes & Findings for Medical Cannabis as an Opiate Alternative (NCT NCT07194928)
NCT ID: NCT07194928
Last Updated: 2026-05-20
Results Overview
The Numeric Rating Scale is measured from Zero which is equivalent to no pain to 10 which indicates the worst possible pain.
Recruitment status
COMPLETED
Target enrollment
29 participants
Primary outcome timeframe
From enrollment monthly until the end of treatment at 5 months
Results posted on
2026-05-20
Participant Flow
Patient were recruited from outpatient chronic pain clinic from 9/1/2024 to 10/1/2025
Participant milestones
| Measure |
Chronic Opioid Pain Patients Were Cost Was Barrier to Trying Medical Marijuana
Chronic opioid patient who were unable to wean off opioid in the past and unable to try medical marijuana secondary to cost. Patient who are eligible will be certified for their medical marijuana card and will go to dispensary to get their medical marijuana.
We will monitor patient's response to medical marijuana as alternative to opioid for chronic pain.: We will monitor patient response to medical marijuana as opioid alternative. This will be given to patient who otherwise could not get intervention secondary to cost. We want to show that medical marijuana is a safer alternative to opioids in this population of patients
|
|---|---|
|
Overall Study
STARTED
|
29
|
|
Overall Study
COMPLETED
|
29
|
|
Overall Study
NOT COMPLETED
|
0
|
Reasons for withdrawal
Withdrawal data not reported
Baseline Characteristics
Medical Cannabis as an Opiate Alternative
Baseline characteristics by cohort
| Measure |
Chronic Opioid Pain Patients Were Cost Was Barrier to Trying Medical Marijuana
n=29 Participants
Chronic opioid patients who were unable to wean off opioid in the past and unable to try medical cannabis secondary to cost. Patient who are eligible will be certified for their medical cannabis card and will go to dispensary to get their medical cannabis.
We will monitor patient's response to medical cannabis as alternative to opioid for chronic pain. We will monitor patient response to medical cannabis as opioid alternative. This will be given to patient who otherwise could not get intervention secondary to cost. We want to show that medical cannabis is a safer alternative to opioids in this population of patients
|
|---|---|
|
Age, Categorical
<=18 years
|
0 Participants
n=30 Participants
|
|
Age, Categorical
Between 18 and 65 years
|
18 Participants
n=30 Participants
|
|
Age, Categorical
>=65 years
|
11 Participants
n=30 Participants
|
|
Age, Continuous
|
63 years
STANDARD_DEVIATION 11.06 • n=30 Participants
|
|
Sex: Female, Male
Female
|
19 Participants
n=30 Participants
|
|
Sex: Female, Male
Male
|
10 Participants
n=30 Participants
|
|
Race (NIH/OMB)
American Indian or Alaska Native
|
0 Participants
n=30 Participants
|
|
Race (NIH/OMB)
Asian
|
0 Participants
n=30 Participants
|
|
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
|
0 Participants
n=30 Participants
|
|
Race (NIH/OMB)
Black or African American
|
25 Participants
n=30 Participants
|
|
Race (NIH/OMB)
White
|
4 Participants
n=30 Participants
|
|
Race (NIH/OMB)
More than one race
|
0 Participants
n=30 Participants
|
|
Race (NIH/OMB)
Unknown or Not Reported
|
0 Participants
n=30 Participants
|
|
Region of Enrollment
United States
|
29 Participants
n=30 Participants
|
|
Baseline pain intensity using Numeric Pain Rating Scale
|
7 units on a 0-10 scale
STANDARD_DEVIATION 1.9 • n=30 Participants
|
|
Baseline opioid dose in Morphine milli-equivalents
|
46.88 mg/day morphine equivalents
STANDARD_DEVIATION 29 • n=30 Participants
|
|
Rand Short Form 36 Questionaire
Physical Functioning score
|
15.34 Scores on a 0-100 scale
n=30 Participants
|
|
Rand Short Form 36 Questionaire
Health Change score
|
38.8 Scores on a 0-100 scale
n=30 Participants
|
PRIMARY outcome
Timeframe: From enrollment monthly until the end of treatment at 5 monthsThe Numeric Rating Scale is measured from Zero which is equivalent to no pain to 10 which indicates the worst possible pain.
Outcome measures
| Measure |
Chronic Opioid Pain Patients Were Cost Was Barrier to Trying Medical Marijuana
n=29 Participants
Chronic opioid patient who were unable to wean off opioid in the past and unable to try medical marijuana secondary to cost. Patient who are eligible will be certified for their medical marijuana card and will go to dispensary to get their medical marijuana.
We will monitor patient's response to medical marijuana as alternative to opioid for chronic pain.: We will monitor patient response to medical marijuana as opioid alternative. This will be given to patient who otherwise could not get intervention secondary to cost. We want to show that medical marijuana is a safer alternative to opioids in this population of patients
|
|---|---|
|
Change in Mean Numeric Rating Scale at 5 Months From Baseline
|
-1.5 Units on a 0-10 scale
Interval -2.0 to -1.1
|
PRIMARY outcome
Timeframe: From Baseline to 5 monthsTotal daily opioid dose was converted to Morphine Milligram Equivalents (MME) using standard opioid conversion tables. The value reported represents the mean change in daily MME from baseline to 5 months. Negative values indicate a reduction in opioid use.
Outcome measures
| Measure |
Chronic Opioid Pain Patients Were Cost Was Barrier to Trying Medical Marijuana
n=29 Participants
Chronic opioid patient who were unable to wean off opioid in the past and unable to try medical marijuana secondary to cost. Patient who are eligible will be certified for their medical marijuana card and will go to dispensary to get their medical marijuana.
We will monitor patient's response to medical marijuana as alternative to opioid for chronic pain.: We will monitor patient response to medical marijuana as opioid alternative. This will be given to patient who otherwise could not get intervention secondary to cost. We want to show that medical marijuana is a safer alternative to opioids in this population of patients
|
|---|---|
|
Change From Baseline to 5 Months in Daily Opioid Use (Morphine Milligram Equivalents)
|
-30.6 Morphine Milligram Equivalents (MME)
Interval -33.0 to -17.0
|
Adverse Events
Chronic Opioid Pain Patients Were Cost Was Barrier to Trying Medical Cannabis
Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths
Serious adverse events
Adverse event data not reported
Other adverse events
Adverse event data not reported
Additional Information
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place